Contents of volume 20

No. 1 (pp 1– 88) published August 10, 1987
No. 2 (pp 89–182) published October 13, 1987
No. 3 (pp 183–270) published November 12, 1987
No. 4 (pp 271–350) published December 14, 1987

This volume contains one supplement:
The Third International Conference on Treatment of Urinary Tract Tumors with Adriamycin. September 26–27, 1986, Tokyo (Suppl) S 1 – S 96 (1987)

Abe O → Kimura K, et al. 223
Abratt RP, Willcox PA, Hewitson RH: Etoposide combination therapy for small cell carcinoma of the lung 83
Adriamycin → Maru A, et al. S 44
Adriamycin → Akaza H, et al. S 91
Ahmann DL → Powis G, et al. 219
Akaza H → Maru A, et al. S 44
Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Maru A, Matsumura Y, Niijima T, Obata K, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Uyama T, The Japanese Urological Cancer Research Group for Adriamycin: Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer S 91
Almersjö O → Berne M, et al. 193
Amaki I → Ohno R, et al. 230
Amano T → Naito K, et al. S 1
Amineddine HA → Pearson ADJ, et al. 243
Ando T, Motokawa I, Sakurai K, Ohmura Y, Fujii T, Matsunaga K, Yoshikumi C, Nomoto K: Influence of PSK (Krestin) on resistance to infection of *Pseudomonas aeruginosa* in tumor-bearing mice 198
Aoyama H → Hirao Y, et al. S 85
Ariyoshi A → Ueda T, et al. S 81
Arundel CM → Tofilon PJ, et al. 89
Asari T → Naito K, et al. S 1
Aso Y → Ohshima S, et al. S 20

Bailey CC → Choonara IA, et al. 349
Banham SW → Milroy R, et al. 75
Basic I → Murray D, et al. 133
Bateman DN → Sviland L, et al. 173
Berne M, Gustavsson B, Almersjö O, Spears CP, Waldenström J: Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver 193
Bernstein L → Grunberg SM, et al. 332
Bibby MC, McDermott BJ, Double JA, Phillips RM, Loadman PM, Burgess L: Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours 203
Birkhead BG → Dones L, et al. 213
Blakley RL → Pemble LB, et al. 155
Blöchl-Daum B → Eichler H-G, et al. 81
Boezeman JBM → Speth PAJ, et al. 305
Boezeman JBM → Speth PAJ, et al. 311
Böhmer RM, Hoffmann K, Morstyn G: Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity 16
Boublil J-L → Milano G, et al. 71
Bouffioux C → Denis L, et al. S 67
Bourry J → Milano G, et al. 71
Boyse O → Gibby EM, et al. 5
Breckenridge S → Soble MJ, et al. 33
Brodie AMH → Cunningham D, et al. 253
Broek LAGM van den → Zylicz Z, et al. 115
Broxterman HJ → Schuurhuis GJ, et al. 285
Brühl P → Mergenthaler H-G, et al. 8
Bruneton J-N → Milano G, et al. 71
Burgess L → Bibby MC, et al. 203

Capizzi RL → Winick NJ, et al. 78
Carcassone Y → Gastaut J-A, et al. 344
Carcassonne Y → Tubiana N, et al. 179
Carenfeldt C → Friberg S, et al. 342
Carlo D → Rosenblum MG, et al. 41
Chan HY, Meyers FJ, Lewis JP: High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia 265
Chessells JM → Pearson ADJ, et al. 243
Choonara IA, Overend M, Bailey CC: Blurring of vision due to ifosfamide 349
Cockett ATK → Mayer RD, et al. 207
Cohen JL → Grunberg SM, et al. 332
Coln D → Winick NJ, et al. 78
Coombes RC → Cunningham D, et al. 253
Coronado E → DeGregorio MW, et al. 316
Cowens JW → Creaven PJ, et al. 37
Craft AW → Pearson ADJ, et al. 243
Craig J → Winick NJ, et al. 78
Creaven PJ, Madajewicz S, Cowens JW, Plager JE, Pendyala L, Mittelman A, Petrelli N, Karakousis C, Huben R, Takita H, Razack MS, Solomon J: Phase I clinical trial of ethyl 6-deoxy-3,5-di-*O*-methyl 6-(3-methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809) 37
Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A, Proefrock A: Phase I clinical trial of recombinant human tumor necrosis factor 137
Creaven PJ, Madajewicz S, Pendyala L, Takita H, Mittelman A, Huben R, Henderson E, Cushman MK: Phase I clinical trial of 1-[2-[2-(4-pyridyl)-2-imidazoline-1-yl]-ethyl]-3-(4-carboxy-phenyl)urea (CGP 15720A) 145
Crowther D → Wagstaff J, et al. 53
Cummings J → Milroy R, et al. 75
Cummings J, Kerr DJ, Kaye SB: Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man 263
Cunningham D, Powles TJ, Dowsett M, Hutchison G, Brodie AMH, Ford HT, Gazet J-C, Coombes RC: Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer 253
Cushman MK → Creaven PJ, et al. 145

Dale BM → Reece PA, et al. 256
David G → Rosenblum MG, et al. 41
Deakin D → Wagstaff J, et al. 53
Debruyne F → Denis L, et al. S 67
Deeb G → Gaver RC, et al. 271
Deen DF → Tofilon PJ, et al. 89
DeGregorio MW, Wilbur BJ, Coronado E, Osborne CK: Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration 316
Denis L, Bouffioux C, Furth KH, Debruyne F, Sylvester R, Pauw M de, Members of the EORTC Urological Group: Current status of intravesical chemotherapy trials in the EORTC Urological Group. An Overview S 67
Deurloo J → Nooter K, et al. 176
Diddens H, Teufel T, Niethammer D: High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines 128
D'Incalci M → Zanette ML, et al. 67
D'Incalci M → Figoli F, et al. 239
Dones L, Wiltshaw E, Birkhead BG, Jackson RRP: Towards an assessment of toxicity in the treatment of ovarian cancer 213
Dorr RT → Soble MJ, et al. 33
Double JA → Bibby MC, et al. 203
Dowsett M → Cunningham D, et al. 253

Dulmadge EA → Wilkoff LJ, et al. 96
Dupere S → Creaven PJ, et al. 137

Edwards CM, Glisson BS, King CK, Smallwood-Kentro S, Ross WE: Etoposide-induced DNA cleavage in human leukemia cells 162
Ehninger G → Mergenthaler H-G, et al. 8
Ehninger G → Schuler U, et al. 248
Ehrsson H → Friberg S, et al. 342
Eichler H-G, Mader R, Blöchl-Daum B, Steger G, Rainer H: Poly (I) · Poly (C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study 81
Eisenhauer E → Jolivet J, et al. 169
Eksborg S → Friberg S, et al. 342
Evans B → Osborne R, et al. 48
Evans PC → Paxton JW, et al. 13

Faucon G → Timour Q, et al. 267
Figoli F → Zanette ML, et al. 67
Figoli F, Zanette ML, Tirelli U, Sorio R, Lestuzzi C, Urso R, Monfardini S, D'Incalci M: Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion 239
Finaud M → Tubiana N, et al. 179
Ford HT → Cunningham D, et al. 253
Frenay M → Milano G, et al. 71
Friberg S, Ehrsson H, Eksborg S, Carenfeldt C: Intratumoral measurement and plasma pharmacokinetics of intravenously administered melphalan. Report of a patient with plasmacytoma 342
Fujihiro S → Kuriyama M, et al. S 29
Fujii T → Ando T, et al. 198
Fujimoto Y → Kuriyama M, et al. S 29
Fujita J → Uyama T, et al. S 10
Fujita T → Ohshima S, et al. S 20
Fukui I, Sekine H, Kihara K, Yamada T, Kawai T, Washizuka M, Ishiwata D, Oka K, Hosoda K, Ikegami S, Sakai K, Ohwada F, Negishi T, Suzuki S, Tohma T, Oshima H: Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors S 52
Fukushima S → Kubota Y, et al. S 56
Furue H → Kimura K, et al. 223
Furuhata A → Kubota Y, et al. S 56

Gallagher C → Osborne R, et al. 48
Gastaut JA → Tubiana N, et al. 179
Gastaut J-A, Tell G, Schechter PJ, Maraninchi D, Mascret B, Carcassone Y: Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG) 344
Gaver RC, George AM, Deeb G: In vitro stability, plasma protein binding and blood cell partitioning of ^{14}C-carboplatin 271
Gazet J-C → Cunningham D, et al. 253
Gee D → Reece PA, et al. 256
George AM → Gaver RC, et al. 271
Gibby EM, Boyse O, Hill BT: Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro 5
Gill PG → Reece PA, et al. 26
Glisson BS → Edwards CM, et al. 162
Griswold DP Jr → Wilkoff LJ, et al. 96
Groeningen CJ van → Peters GJ, et al. 101
Grunberg SM, McDermed JE, Bernstein L, Cohen JL: Examination of the correlation of serum metoclopramide levels with antiemetic efficacy in patients receiving cisplatin 332
Gustavsson B → Berne M, et al. 193

Haanen C → Speth PAJ, et al. 305
Haanen C → Speth PAJ, et al. 311
Haelst U van → Zylicz Z, et al. 115
Hagen B, Nilsen OG: The binding of thio-TEPA in human serum and to isolated serum protein fractions 319
Hahn GM → Rice GC 183
Harper PG → Philip PA, et al. 235
Harrison SD Jr → Wilkoff LJ, et al. 96
Hashimoto M → Hirao Y, et al. S 85
Hattori T → Kimura K, et al. 223
Havemann K → Pflüger K-H, et al. 59
Hegedüs L, Vijgh WJF van der, Klein I, Kerpel-Fronius S, Pinedo HM: Chemical reacitivity of cisplatin bound to human plasma proteins 211
Heidemann E → Mergenthaler H-G, et al. 8
Hellmann K, Hutchinson GE, Henry K: Reduction of vincristine toxicity by Cronassial 21
Henderson E → Creaven PJ, et al. 145
Henry K → Hellmann K, et al. 21
Hewitson RH → Abratt RP, et al. 83
Higa I → Uyama T, et al. S 10
Higa T → Isaka S, et al. S 77
Hill BT → Gibby EM, et al. 5
Hiramatsu T → Hirao Y, et al. S 85
Hirano A → Uekado Y, et al. S 24
Hirano M → Ohno R, et al. 230
Hirao Y, Okajima E, Ohara S, Ozono S, Hiramatsu T, Yoshida K, Yamada K, Aoyama H, Hashimoto M, Watanabe S: Prophylactic treatment for superficial bladder cancer following transurethral resection S 85
Hisazumi H → Naito K, et al. S 1
Hoeven JJM van der → Schuurhuis GJ, et al. 285
Höffken K → Miller AM, et al. 337
Hoffmann K → Böhmer RM, et al. 16
Horchowski N → Tubiana N, et al. 179
Hosaka M → Kubota Y, et al. S 56
Hoshi A → Iigo M, et al. 1
Hoshino A → Ohno R, et al. 230
Hosoda K → Fukui I, et al. S 52
Huben R → Creaven PJ, et al. 37
Huben R → Creaven PJ, et al. 145
Huben RP → Creaven PJ, et al. 137
Hutchinson GE → Hellmann K, et al. 21
Hutchison G → Cunningham D, et al. 253

Ichihashi H → Kimura K, et al. 223
Idriss JM → Israel M, et al. 277
Igarashi T → Isaka S, et al. S 77
Iguchi A → Ueda T, et al. S 81
Iigo M, Yamaizumi Z, Nishimura S, Hoshi A: Elevation of plasma levels of fluorinated pyrimidines by guanosine 5'-monophosphate 1
Ikeda Y → Ohno R, et al. 230
Ikegami S → Fukui I, et al. S 52
Ingle JN → Powis G, et al. 219
Inoguchi K → Kimura K, et al. 223
Isaka S → Maru A, et al. S 44
Isaka S, Okano T, Shimazaki J, Igarashi T, Murakami S, Higa T, Ishikawa T, Zama S, Kataumi S, Kataumi Z, Kitamura Y: Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C S 77
Isaka S → Akaza H, et al. S 91
Ishikawa S → Kanoh S, et al. S 6
Ishikawa T → Isaka S, et al. S 77
Ishiwata D → Fukui I, et al. S 52
Israel M, Idriss JM, Koseki Y, Khetarpal VK: Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro 277

Jackson RRP → Dones L, et al. 213
Jamieson GP → Pemble LB, et al. 155
Jolivet J, Landry L, Pinard M-F, McCormack JJ, Tong WP, Eisenhauer E: A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections 169

Jones M → Wagstaff J, et al. 53
Judson JR: *Letter to the editors* 181
Jungclas H → Pflüger K-H, et al. 59

Kakizaki H, Suzuki H, Kubota Y, Numasawa K, Suzuki K: Preoperative one-shot intra-arterial infusion chemotherapy for bladder cancer S 15
Kamen BA → Winick NJ, et al. 78
Kanoh S, Noguchi R, Ohtani M, Ishikawa S, Nemoto R, Koiso K, Kitagawa R: Intra-arterial chemotherapy for bladder cancer S 6
Karakousis C → Creaven PJ, et al. 37
Kataumi S → Isaka S, et al. S 77
Kataumi Z → Isaka S, et al. S 77
Kawai T → Fukui I, et al. S 52
Kaye SB → Milroy R, et al. 75
Kaye SB → Cummings J, et al. 263
Kerpel-Fronius S → Hegedüs L, et al. 211
Kerr DJ → Cummings J, et al. 263
Khan M → Reece PA, et al. 26
Khater R → Milano G, et al. 71
Khetarpal VK → Israel M, et al. 277
Kihara K → Fukui I, et al. S 52
Kimura I → Ohno R, et al. 230
Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, Niitani H, Ota K, Saito T, Suga S, Suzuoki Y, Wakui A, Yamada K, The A-TNF Cooperative Study Group: Phase I study of recombinant human tumor necrosis factor 223
Kimura K → Ohno R, et al. 230
King CK → Edwards CM, et al. 162
Kinouchi T → Kiyohara H, et al. S 34
Kitada K → Uyama T, et al. S 10
Kitagawa R → Kanoh S, et al. S 6
Kitamura Y → Isaka S, et al. S 77
Kiyohara H, Kuroda M, Saiki S, Miki T, Kinouchi T, Usami M, Kotake T: Postoperative systemic adjuvant chemotherapy for bladder cancer S 34
Kleijn E van der → Zylicz Z, et al. 115
Klein I → Hegedüs L, et al. 211
Kobashi K → Naito K, et al. S 1
Kobayashi M → Ohno R, et al. 230
Koiso K → Kanoh S, et al. S 6
Koiso K → Maru A, et al. S 44
Koiso K → Akaza H, et al. S 91
Kondo I → Kubota Y, et al. S 56
Konno K → Ohno R, et al. 230
Kooistra KL → Powis G 291
Koseki Y → Israel M, et al. 277
Kotake T → Kiyohara H, et al. S 34
Kotake T → Maru A, et al. S 44
Kotake T → Akaza H, et al. S 91
Kotasek D → Reece PA, et al. 256
Kubota Y → Kakizaki H, et al. S 15
Kubota Y, Noguchi S, Shuin T, Moriyama M, Hosaka M, Satomi Y, Furuhata A, Kondo I, Sakuramoto T, Yao M, Fukushima S: Preoperative doxorubicin instillation in recurrent superficial bladder cancer S 56
Kumazawa J → Ueda T, et al. S 81
Kuriyama M, Takeuchi T, Fujihiro S, Fujimoto Y, Shinoda I, Takahashi Y, Yamada S, Nishiura T: Adjuvant chemotherapy for urothelial transitional cell carcinoma S 29
Kuroda M → Kiyohara H, et al. S 34
Kurth KH → Denis L, et al. S 67

Lakhal M → Timour Q, et al. 267
Lamki L → Rosenblum MG, et al. 41
Lam YM → Shiu W, et al. 259
Landry L → Jolivet J, et al. 169
Lang J → Timour Q, et al. 267
Lankelma J → Peters GJ, et al. 101
Lankelma J → Schuurhuis GJ, et al. 285
Laurensse EJ → Peters GJ, et al. 101
Lee K → Mayer RD, et al. 207
Lejeune C → Tubiana N, et al. 179
Lestuzzi C → Figoli F, et al. 239
Lewis JP → Chan HY, et al. 265
Leyva A → Peters GJ, et al. 101
Lihou MG → Pemble LB, et al. 155
Linssen PCM → Speth PAJ, et al. 305
Linssen PCM → Speth PAJ, et al. 311
Lipton A: The anti-oestrogen tamoxifen is a calcium antagonist in perfused rat mesentery 125
Loadman PM → Bibby MC, et al. 203
Long DR → Pearson ADJ, et al. 243

Machida T → Maru A, et al. S 44
Machida T → Akaza H, et al. S 91
Madajewicz S → Creaven PJ, et al. 37
Madajewicz S → Creaven PJ, et al. 145
Mader R → Eichler H-G, et al. 81
Maessen PA, Mross KB, Pinedo HM, Vijgh WJF van der: Metabolism of epidoxorubicin in animals: absence of glucuronidation 85
Majima H → Kimura K, et al. 223
Majima H → Ohno R, et al. 230
Maraninchi D → Gastaut J-A, et al. 344
Marris M → Wagstaff J, et al. 53
Martin WMC → Shiu W, et al. 259
Maru A, Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Matsumura Y, Nakagami Y, Niijima T, Obata K, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Uyama T, The Japanese Urological Cancer Research Group for Adriamycin: Phase III trial of The Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder S 44
Maru A → Akaza H, et al. S 91
Masaoka T → Ohno R, et al. 230
Mascret B → Gastaut J-A, et al. 344
Matsumura Y → Maru A, et al. S 44
Matsumura Y → Obama T, et al. S 60
Matsumura Y → Tsushima T, et al. S 72
Matsumura Y → Akaza H, et al. S 91
Matsunaga K → Ando T, et al. 198
Mayer RD, Lee K, Cockett ATK: Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor 207
McCormack JJ → Jolivet J, et al. 169
McDermed JE → Grunberg SM, et al. 332
McDermott BJ → Bibby MC, et al. 203
McGuirt F → Winick NJ, et al. 78
Members of the EORTC GU Tract Cooperative Group → Newling DWW, et al. S 39
Members of the EORTC Urological Group → Denis L, et al. S 67
Mergenthaler H-G, Brühl P, Ehninger G, Heidemann E: Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells 8
Merkel M → Pflüger K-H, et al. 59
Meyers FJ → Chan HY, et al. 265
Meyn RE → Murray D, et al. 133
Mihara S → Naito K, et al. S 1
Miki T → Kiyohara H, et al. S 34
Milano G, Namer M, Boublil J-L, Khater R, Frenay M, Thyss A, Bourry J, Philip C, Renée N, Bruneton J-N: Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy 71
Milas L → Murray D, et al. 133
Miller AM, Miller BE, Höffken K, Schmidt CG: Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer 337
Miller BE → Miller AM, et al. 337

Mills S → Pearson ADJ, et al. 243
Milroy R, Cummings J, Kaye SB, Banham SW: Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer 75
Mittelman A → Creaven PJ, et al. 37
Mittelman A → Creaven PJ, et al. 137
Mittelman A → Creaven PJ, et al. 145
Mizuno H → Ohno R, et al. 230
Monfardini S → Zanette ML, et al. 67
Monfardini S → Figoli F, et al. 239
Moral PF del → Zylicz Z, et al. 115
Moriwaki S → Uyama T, et al. S 10
Moriyama M → Kubota Y, et al. S 56
Morris RG → Reece PA, et al. 256
Morstyn G → Böhmer RM, et al. 16
Motokawa I → Ando T, et al. 198
Mross KB → Maessen PA, et al. 85
Murakami S → Isaka S, et al. S 77
Murray D, Basic I, Milas L, Meyn RE: DNA cross-linking following exposure to *cis*-platinum in primary and serially passaged cultured cells derived from two fibrosarcomas 133
Murray JL → Rosenblum MG, et al. 41

Naito K, Hisazumi H, Mihara S, Asari T, Kobashi K, Amano T, Uchibayashi T: Chemosensitivity study of urological malignancies using a novel dye-exclusion method S 1
Nakagami Y → Maru A, et al. S 44
Nakagawa S → Watanabe H, et al. S 49
Nakao M → Watanabe H, et al. S 49
Namer M → Milano G, et al. 71
Negishi T → Fukui I, et al. S 52
Nemoto R → Kanoh S, et al. S 6
Newling DWW, Stoter G, Sylvester R, Pauw M de, Members of the EORTC GU Tract Cooperative Group: The chemotherapy of advanced bladder cancer S 39
Niethammer D → Diddens H, et al. 128
Niijima T → Maru A, et al. S 44
Niijima T → Akaza H, et al. S 91
Niitani H → Kimura K, et al. 223
Nilsen OG → Hagen B 319
Nishimura S → Iigo M, et al. 1
Nishiura T → Kuriyama M, et al. S 29
Noguchi R → Kanoh S, et al. S 6
Noguchi S → Kubota Y, et al. S 56
Noker PE, Simpson-Herren L, Wagoner SD: Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors 188
Noker PE → Simpson-Herren L, et al. 297
Nomoto K → Ando T, et al. 198
Nomura F, Shimokata K, Saito H, Sakai S, Watanabe A, Saka H: Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer 324
Nony P → Timour Q, et al. 267
Nooter K, Oostrum R, Deurloo J: Effects of verapamil on the pharmacokinetics of daunomycin in the rat 176
Numasawa K → Kakizaki H, et al. S 15

Obama T, Matsumura Y, Ohmori H, Okayama Urological Cancer Collaborative Group (OUCCG): Intravesical chemotherapy S 60
Obata K → Maru A, et al. S 44
Obata K → Akaza H, et al. S 91
Ogawa M → Ohno R, et al. 230
Oguro M → Takagi T 151
Oguro M → Ohno R, et al. 230
Ohara S → Hirao Y, et al. S 85
Ohe H → Maru A, et al. S 44
Ohe H → Akaza H, et al. S 91
Ohi Y → Maru A, et al. S 44
Ohi Y → Akaza H, et al. S 91
Ohkawa T → Uekado Y, et al. S 24
Ohmori H → Obama T, et al. S 60
Ohmori H → Tsushima T, et al. S 72
Ohmura Y → Ando T, et al. 198
Ohno R → Kimura K, et al. 223
Ohno R, Kimura K, Amaki I, Hirano M, Hoshino A, Ikeda Y, Kimura I, Kobayashi M, Konno K, Majima H, Masaoka T, Mizuno H, Ogawa M, Oguro M, Saito T, Shimoyama M, Shirakawa S, Sugawara Y, Takaku F, Yamada H, Yamada K, Yamagata K, Yoshida Y, Yoshikawa S, Wakui A, The THP Study Group on Hematological Malignancy: Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin 230
Ohshima S, Ono Y, Fujita T, Aso Y: Three-drug combination chemotherapy for advanced urothelial tract carcinoma S 20
Ohtani M → Kanoh S, et al. S 6
Ohwada F → Fukui I, et al. S 52
Okajima E → Hirao Y, et al. S 85
Oka K → Fukui I, et al. S 52
Okano T → Isaka S, et al. S 77
Okayama Urological Cancer Collaborative Group Okayama Urological Cancer Collaborating Group Omoto T → Ueda T, et al. S 81
Ono Y → Ohshima S, et al. S 20
Oostrum R → Nooter K, et al. 176
Osada Y → Ueda T, et al. S 81
Osborne CK → DeGregorio MW, et al. 316
Osborne R, Evans B, Gallagher C, Wood C, Slevin M, Shepherd J, Wiltshaw E: High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer 48
Oshima H → Fukui I, et al. S 52
Ota K → Kimura K, et al. 223
Ottenheijm HCJ → Zylicz Z, et al. 115
(OUCCG) → Obama T, et al. S 60
(OUCCG) → Tsushima T, et al. S 72
Overend M → Choonara IA, et al. 349
Ozaki Y → Tsushima T, et al. S 72
Ozono S → Hirao Y, et al. S 85

Pauw M de → Newling DWW, et al. S 39
Pauw M de → Denis L, et al. S 67
Paxton JW, Evans PC, Singh RM: Dose-dependent pharmacokinetics of *N*-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino) phenylamino]-4-acridinecarboxamide (CI-921) in rabbits 13
Pearson ADJ, Mills S, Amineddine HA, Long DR, Craft AW, Chessells JM: Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia 243
Pemble LB, Lihou MG, Blakley RL, Jamieson GP, Smith PJ: Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells 155
Pendyala L → Creaven PJ, et al. 37
Pendyala L → Creaven PJ, et al. 145
Peters GJ, Groeningen CJ van, Laurensse EJ, Lankelma J, Leyva A, Pinedo HM: Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites 101
Petrelli N → Creaven PJ, et al. 37
Pflüger K-H, Schmidt L, Merkel M, Jungclas H, Havemann K: Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical biochemical data from patients receiving etoposide 59
Philip C → Milano G, et al. 71
Philip PA, Rogers HJ, Harper PG: Acetylation and oxidation phenotypes in malignant lymphoma 235
Phillips RM → Bibby MC, et al. 203
Pinard M-F → Jolivet J, et al. 169
Pinedo HM → Maessen PA, et al. 85
Pinedo HM → Peters GJ, et al. 101
Pinedo HM → Hegedüs L, et al. 211
Pinedo HM → Schuurhuis GJ, et al. 285
Plager JE → Creaven PJ, et al. 37

Plager JE → Creaven PJ, et al. 137
Plezia P → Soble MJ, et al. 33
Powis G, Reece P, Ahmann DL, Ingle JN: Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients 219
Powis G, Kooistra KL: Doxorubicin-induced hair loss in the Angora rabbit: a study of treatments to protect against the hair loss 291
Powles TJ → Cunningham D, et al. 253
Proctor SJ → Sviland L, et al. 173
Proefrock A → Creaven PJ, et al. 137

Rainer H → Eichler H-G, et al. 81
Razack MS → Creaven PJ, et al. 37
Reece P → Powis G, et al. 219
Reece PA, Stafford I, Russell J, Khan M, Gill PG: A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin 26
Reece PA, Dale BM, Morris RG, Kotasek D, Gee D, Rogerson S, Sage RE: Effect of L-leucine on oral melphalan kinetics in patients 256
Renée N → Milano G, et al. 71
Rennes H van → Zylicz Z, et al. 115
Rice GC, Hahn GM: Modulation of adriamycin transport by hyperthermia as measured by fluorescence-activated cell sorting 183
Robinson A → Sviland L, et al. 173
Rogers HJ → Philip PA, et al. 235
Rogerson S → Reece PA, et al. 256
Rosenblum MG, Murray JL, Lamki L, David G, Carlo D: Comparative clinical pharmacology of [^{111}In]-labeled murine monoclonal antibodies 41
Ross WE → Edwards CM, et al. 162
Russell J → Reece PA, et al. 26
Rutty CJ: *Letter to the editors* 181

Sage RE → Reece PA, et al. 256
Sagiyama K → Ueda T, et al. S 81
Saiki S → Kiyohara H, et al. S 34
Sainty D → Tubiana N, et al. 179
Saito H → Nomura F, et al. 324
Saito T → Kimura K, et al. 223
Saito T → Ohno R, et al. 230
Saka H → Nomura F, et al. 324
Sakai K → Fukui I, et al. S 52
Sakai S → Nomura F, et al. 324
Sakurai K → Ando T, et al. 198
Sakuramoto T → Kubota Y, et al. S 56
Satomi Y → Kubota Y, et al. S 56
Scarffe H → Smith D, et al. 327
Scarffe JH → Wagstaff J, et al. 53
Schechter PJ → Gastaut J-A, et al. 344
Schmidt CG → Miller AM, et al. 337
Schmidt L → Pflüger K-H, et al. 59
Schuler U, Ehninger G, Wagner T: Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites 248
Schuurhuis GJ, Broxterman HJ, Hoeven JJM van der, Pinedo HM, Lankelma J: Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil 285
Sebahoun G → Tubiana N, et al. 179
Sekine H → Fukui I, et al. S 52
Shepherd J → Osborne R, et al. 48
Shimazaki J → Maru A, et al. S 44
Shimazaki J → Isaka S, et al. S 77
Shimazaki J → Akaza H, et al. S 91
Shimokata K → Nomura F, et al. 324
Shimoyama M → Ohno R, et al. 230
Shinka T → Uekado Y, et al. S 24
Shinoda I → Kuriyama M, et al. S 29
Shiotsu T → Uyama T, et al. S 10
Shirakawa S → Ohno R, et al. 230
Shiu W, Tsang V, Lam YM, Zacharia A, Martin WMC: A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil 259
Shuin T → Kubota Y, et al. S 56
Simpson-Herren L → Noker PE, et al. 188
Simpson-Herren L, Noker PE, Wagoner SD: Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity 297
Singh RM → Paxton JW, et al. 13
Sklar F → Winick NJ, et al. 78
Slevin M → Osborne R, et al. 48
Smallwood-Kentro S → Edwards CM, et al. 162
Smith D, Wagstaff J, Thatcher N, Scarffe H: A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion 327
Smith PJ → Pemble LB, et al. 155
Soble MJ, Dorr RT, Plezia P, Breckenridge S: Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics 33
Solomon J → Creaven PJ, et al. 37
Sorio R → Zanette ML, et al. 67
Sorio R → Figoli F, et al. 239
Spears CP → Berne M, et al. 193
Speth PAJ, Linssen PCM, Boezeman JBM, Wessels HMC, Haanen C: Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients 305
Speth PAJ, Linssen PCM, Boezeman JBM, Wessels HMC, Haanen C: Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion 311
Stafford I → Reece PA, et al. 26
Steger G → Eichler H-G, et al. 81
Stoter G → Newling DWW, et al. S 39
Stratford IJ → West CML 109
Streckfuss A → Winick NJ, et al. 78
Suga S → Kimura K, et al. 223
Sugawara Y → Ohno R, et al. 230
Suzuki H → Kakizaki H, et al. S 15
Suzuki K → Kakizaki H, et al. S 15
Suzuki S → Fukui I, et al. S 52
Suzuoki Y → Kimura K, et al. 223
Sviland L, Robinson A, Proctor SJ, Bateman DN: Interaction of cimetidine with oral melphalan. A pharmacokinetic study 173
Sylvester R → Newling DWW, et al. S 39
Sylvester R → Denis L, et al. S 67

Taguchi T → Kimura K, et al. 223
Takada H → Watanabe H, et al. S 49
Takagi T, Oguro M: (2"-*R*)-4'-*o*-Tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies 151
Takahashi Y → Kuriyama M, et al. S 29
Takaku F → Ohno R, et al. 230
Takeuchi T → Kuriyama M, et al. S 29
Takita H → Creaven PJ, et al. 37
Takita H → Creaven PJ, et al. 137
Takita H → Creaven PJ, et al. 145
Tashiro K → Maru A, et al. S 44
Tashiro K → Akaza H, et al. S 91
Tell G → Gastaut J-A, et al. 344
Teufel T → Diddens H, et al. 128
Thatcher N → Smith D, et al. 327
The A-TNF Cooperative Study Group → Kimura K, et al. 223
The Japanese Urological Cancer Research Group for The Japanese Urological Cancer Research Group for The Kyushu University Urological Oncology Group → Ueda T, et al. S 81
The THP Study Group on Hematological Malignancy → Ohno R, et al. 230

Thyss A → Milano G, et al. 71
Timour Q, Nony P, Lang J, Lakhal M, Trillet V, Faucon G: Doxorubicin concentration time course in the myocardium after single administration to the dog. Possible role in the cardiac effects 267
Tirelli U → Zanette ML, et al. 67
Tirelli U → Figoli F, et al. 239
Todd I → Wagstaff J, et al. 53
Tofilon PJ, Arundel CM, Deen DF: Response to BCNU of spheroids grown from mixtures of drug-sensitive and drug-resistant cells 89
Tohma T → Fukui I, et al. S 52
Tong WP → Jolivet J, et al. 169
Torti FM: Approaches to the treatment of bladder cancer at Stanford S 63
Trader MW → Wilkoff LJ, et al. 96
Trillet V → Timour Q, et al. 267
Tsang V → Shiu W, et al. 259
Tsushima T, Matsumura Y, Ozaki Y, Yoshimoto J, Ohmori H, Okayama Urological Cancer Collaborating Group (OUCCG): Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer S 72
Tubiana N, Lejeune C, Horchowski N, Gastaut JA, Finaud M, Sainty D, Sebahoun G, Carcassonne Y: Etoposide and *cis*-platinum in resistant lymphomas 179

Uchibayashi T → Naito K, et al. S 1
Ueda T → Maru A, et al. S 44
Ueda T, Iguchi A, Sagiyama K, Osada Y, Ariyoshi A, Omoto T, Kumazawa J, The Kyushu University Urological Oncology Group: Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results S 81
Ueda T → Akaza H, et al. S 91
Uekado Y, Shinka T, Hirano A, Ohkawa T: Adjuvant chemotherapy for invasive bladder cancer S 24
Urso R → Figoli F, et al. 239
Urushizaki I → Kimura K, et al. 223
Usami M → Kiyohara H, et al. S 34
Uyama T, Moriwaki S, Yokozeki A, Kitada K, Higa I, Shiotsu T, Fujita J: The role of preoperative intra-arterial doxorubicin chemotherapy in combination with low-dose irradiation for bladder cancer S 10
Uyama T → Maru A, et al. S 44
Uyama T → Akaza H, et al. S 91

Vijgh WJF van der → Maessen PA, et al. 85
Vijgh WJF van der → Hegedüs L, et al. 211
Vree TB → Zylicz Z, et al. 115

Wagener DJT → Zylicz Z, et al. 115
Wagner T → Schuler U, et al. 248
Wagoner SD → Noker PE, et al. 188
Wagoner SD → Simpson-Herren L, et al. 297
Wagstaff J, Todd I, Deakin D, Wilkinson P, Scarffe JH, Marris M, Jones M, Crowther D: A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma 53
Wagstaff J → Smith D, et al. 327
Wakui A → Kimura K, et al. 223
Wakui A → Ohno R, et al. 230
Waldenström J → Berne M, et al. 193
Washizuka M → Fukui I, et al. S 52
Watanabe A → Nomura F, et al. 324
Watanabe H, Nakao M, Nakagawa S, Takada H: Size and location of tumors influencing the effect of bladder instillation therapy S 49
Watanabe S → Hirao Y, et al. S 85
Wessels HMC → Speth PAJ, et al. 305
Wessels HMC → Speth PAJ, et al. 311
Wessels JMC → Zylicz Z, et al. 115
West CML, Stratford IJ: A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids 109
Wilbur BJ → DeGregorio MW, et al. 316
Wilkinson P → Wagstaff J, et al. 53
Wilkoff LJ, Dulmadge EA, Trader MW, Harrison SD Jr, Griswold DP Jr: Evaluation of *trans*-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to *cis*-diamminedichloroplatinum (II) 96
Willcox PA → Abratt RP, et al. 83
Wiltshaw E → Osborne R, et al. 48
Wiltshaw E → Dones L, et al. 213
Winick NJ, Kamen BA, Streckfuss A, Craig J, McGuirt F, Capizzi RL, Sklar F, Coln D: Methotrexate (MTX) concentration in tumors following low-dose MTX 78
Winograd B → Zylicz Z, et al. 115
Wood C → Osborne R, et al. 48

Yamada H → Ohno R, et al. 230
Yamada K → Kimura K, et al. 223
Yamada K → Ohno R, et al. 230
Yamada K → Hirao Y, et al. S 85
Yamada S → Kuriyama M, et al. S 29
Yamada T → Fukui I, et al. S 52
Yamagata K → Ohno R, et al. 230
Yamaizumi S → Iigo M, et al. 1
Yao M → Kubota Y, et al. S 56
Yokozeki A → Uyama T, et al. S 10
Yoshida K → Hirao Y, et al. S 85
Yoshida Y → Ohno R, et al. 230
Yoshikawa S → Ohno R, et al. 230
Yoshikumi C → Ando T, et al. 198
Yoshimoto J → Tsushima T, et al. S 72

Zacharia A → Shiu W, et al. 259
Zadro D → Zanette ML, et al. 67
Zama S → Isaka S, et al. S 77
Zanette ML, Tirelli U, Sorio R, Zadro D, Figoli F, Monfardini S, D'Incalci M: Pharmacokinetics of 7-con-*O*-methylnogarol in patients with solid tumors 67
Zanette ML → Figoli F, et al. 239
Zylicz Z, Wagener DJT, Moral PF del, Rennes H van, Wessels JMC, Winograd B, Kleijn E van der, Vree TB, Haelst U van, Broek LAGM van den, Ottenheijm HCJ: Pharmacokinetics and toxicology of sparsomycin in beagle dogs 115